The IPO8 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population generated from the NCI-H1975 human lung adenocarcinoma cell line to disrupt the IPO8 gene. This polyclonal pool provides a heterogeneous collection of gene disruptions at the target locus, minimizing clonal artifacts and enabling robust functional analysis in a cancer-relevant background.
NCI-H1975 is a widely used and well-characterized model of non-small cell lung adenocarcinoma (NSCLC) derived from a metastatic site, carrying activating EGFR mutations (L858R, T790M) and a TP53 mutation. The T790M substitution confers resistance to first-generation EGFR tyrosine kinase inhibitors, making these cells particularly suitable for studies of acquired drug resistance. Their mesenchymal-like phenotype further supports investigations of cell migration and invasion.
IPO8 encodes importin-8, a nuclear transport receptor that recognizes classical nuclear localization signals (NLS) in conjunction with importin alpha and RanGTP. Established cargoes include SMAD4, the central transcriptional mediator of TGF-beta signaling; the NF-kB subunit RELA (p65); and the nucleoporin ELYS. Thus, IPO8 acts downstream of TGFBR1 activation and SMAD2/3 phosphorylation, and downstream of IKK-mediated NFKBIA degradation, to mediate nuclear translocation of SMAD4 and NF-kB p65, respectively.
In NCI-H1975 cells, disruptive mutations in IPO8 can impair nuclear import of SMAD4 and NF-kB p65, potentially attenuating TGF-beta- and NF-kB-dependent transcriptional programs that regulate proliferation, epithelial-mesenchymal transition, apoptosis, and metastasis. This model offers a direct means to investigate how nuclear transport defects influence lung adenocarcinoma progression and the interplay between nuclear import and EGFR inhibitor sensitivity, particularly in the context of the T790M resistance mutation.
Recommended applications include immunofluorescence-based localization of SMAD4 or RELA; dual-luciferase reporter assays for TGF-beta/NF-kB pathway activity; wound healing and colony formation assays to assess cell migration and clonogenicity; and dose-response studies with EGFR inhibitors such as osimertinib. The cells are also suited for western blotting, RT-qPCR, and functional genomics screening. For further information, custom orders, or technical support, please contact Ascent Research.
